July 7, 2021 7:31am

Pre-open indications: 4 BUYs: AGTC, CRSP, EDIT, NTLA; 1 Sell: SGMO; 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming in July, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are UP +0.09% (+30 points), S&P futures are UP +0.19% (+8 point) and NASDAQ futures are UP +0.56% (+83 points)

 

U.S. stock futures are slightly higher on Wednesday,

European stocks moved higher

Asia-Pacific stocks were mixed

 

Data Docket: more clues on the direction of the Fed’s monetary policy; weekly mortgage applications and the Job Openings and Labor Turnover Survey.

 

Henry’omics:

Investors may be worried the economy might be approaching its peak and that a correction could be on the way. In addition to complacency in the market, the combination of profit-margin pressures, inflation fears, Fed tapering and possible higher taxes could contribute to an eventual drawdown, market strategists say. <CNBC>

The Nasdaq rose to a fresh all-time high on Tuesday

 

Tuesday’s evening’s recap: “the cell and gene therapy sector collapsed again as cashing-out killed any trend as gene editors got creamed” … https://www.regmedinvestors.com/articles/11986

  • The Nasdaq closed up +24.32 points (+0.17%);
  • The IBB closed down -1.14% and XBI closed down -2.15%
  • Sector volume was LOW with 1 of the 7-upside having higher than the 3-month average volume with LOW volume of 5 of 26-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +1.37 points or +9.09% at 16.44;
  • Tuesday’s percentage (%) of the 7-upside were +0.51% (VSTM) to +11.11% (BSTG) while the 26-downside ranges from -0.65% (CLBS) to -12.31% (EDIT);

 

Q3/21: 1 positive and 2 negative close

Q2/21:

  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – Could the share price stay up if it wasn’t “pumped”?

Biostage (BSTG) closed up +$0.15 to $1.50 with 5,702 shares traded after Friday’s -$0.00 with 1,974 shares traded after Thursday’s +$0.095 to $1.35 with 408 shares traded following Wednesday’s -$0.005 to $1.25 with 3,241 shares traded, Tuesday’s +$0.03 to $1.26 with 1,860 shares traded, Monday’s -$0.02 to $1.23 with 1,177 shares traded and last Friday’s -$0.10 to $1.25 with 1,00 shares traded.

Question#1: WHAT role is DST Capital “playing” in these on-going “volume-pumping” pricing “moves” – to exercise the remaining outstanding warrants to add even more unregistered shares to the “outstanding”?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

BUY from SELL:

CRISPR Therapeutics (CRSP) closed down -$7.78 to $148.10 after Friday’s -$0.76 to $165.88, Thursday’s -$5.25 to $156.64 and last Wednesday’s +$11.40 to $161.89 with a positive +$1.90 or +1.28% pre-market indication.

Editas Medicine (EDIT) closed down -$6.76 to $48.14 after Friday’s -$1.62 to $54.90, Thursday’s -$0.12 to $56.52 and Wednesday’s +$10.54 to $56.64 with a positive +$1.75 or +3.64% pre-market indication.

 

BUY:

Applied Genetic Technologies (AGTC) closed down -$0.26 to $3.86 after Friday’s +$0.10 to $4.12 and has a positive +$0.07 or +1.81% pre-market indication;

Intellia Therapeutics (NTLA) closed down -$14.26 to $149.45 after Friday’s -$7.94 to $163.71, Thursday’s +$9.74 to $171.65 and last Wednesday’s +$10.30 to $161.91 with a positive +$4.05 or +2.71% pre-market indication even after closing a $600 M offering at $145.00.

SELL:

Sangamo Therapeutics (SGMO) closed down -$0.46 to $11.25 after Friday’s -$0.30 to $11.71 with a negative -$0.14 or -1.24% pre-market indication

 

The BOTTOM LINE: It takes courage to not being discouraged by this sector …

In my role as a research analyst and journalist is a balancing “act”, WHAT CHANGES; many times, I scratch my head over how to cover volatile cell and gene therapy equities – it’s the INDICATIONS that focus my “leanings”.

I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.